Belite Bio (BLTE) Preferred Stock Liabilities (2020 - 2021)
Belite Bio's quarterly Preferred Stock Liabilities came in at $31.8 million in Q4 2021, little changed year-on-year from $31.8 million in Q4 2020, and little changed quarter-over-quarter from $31.8 million in Q4 2020.
Belite Bio has reported Preferred Stock Liabilities for 2 years, with the latest figure at $31.8 million in Q4 2021.
- For the quarter ending Q4 2021, Preferred Stock Liabilities changed 0.0% year-over-year to $31.8 million; the trailing twelve-month figure through Dec 2021 stood at $31.8 million (changed 0.0% YoY), and the FY2021 full-year result was $31.8 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities for Q4 2021 stood at $31.8 million, roughly flat from $31.8 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $31.8 million in Q4 2020, with the low at $31.8 million in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Belite Bio | 4.92 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 31.81 Mn |
| Dec 31, 2020 | 31.81 Mn |